Welcome to the InformCLL Study at MHOA
Now enrolling patients for the InformCLL Registry. The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens.
This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL).
MHOA Principle Investigator
Alec Goldenberg, M.D.